191 related articles for article (PubMed ID: 37205758)
1. Desensitization and belatacept-based maintenance therapy in pregnancy-sensitized monkeys receiving a kidney transplant.
Manook M; Olaso D; Anwar IJ; Yoon J; Delaura I; Bae Y; Moris D; Shaw B; Song M; Farris AB; Jackson A; Kwun J; Knechtle S
Sci Adv; 2023 May; 9(20):eadg1448. PubMed ID: 37205758
[TBL] [Abstract][Full Text] [Related]
2. Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients.
Ezekian B; Schroder PM; Mulvihill MS; Barbas A; Collins B; Freischlag K; Yoon J; Yi JS; Smith F; Olaso D; Saccoccio FM; Permar S; Farris AB; Kwun J; Knechtle SJ
J Am Soc Nephrol; 2019 Dec; 30(12):2399-2411. PubMed ID: 31658991
[TBL] [Abstract][Full Text] [Related]
3. Belatacept-Based Maintenance Immunosuppression Controls the Post-Transplant Humoral Immune Response in Highly Sensitized Nonhuman Primates.
Schmitz R; Fitch ZW; Manook M; Schroder PM; Choi AY; Olaso D; Yoon J; Bae Y; Shaw BI; Song M; Kuchibhatla M; Farris AB; Kirk A; Kwun J; Knechtle SJ
Kidney360; 2022 Dec; 3(12):2116-2130. PubMed ID: 36591367
[TBL] [Abstract][Full Text] [Related]
4. Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model.
Schroder PM; Schmitz R; Fitch ZW; Ezekian B; Yoon J; Choi AY; Manook M; Barbas A; Leopardi F; Song M; Farris AB; Collins B; Kwun J; Knechtle SJ
Kidney Int; 2021 Jan; 99(1):161-172. PubMed ID: 32898569
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting: Combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients.
Burghuber CK; Manook M; Ezekian B; Gibby AC; Leopardi FV; Song M; Jenks J; Saccoccio F; Permar S; Farris AB; Iwakoshi NN; Kwun J; Knechtle SJ
Am J Transplant; 2019 Mar; 19(3):724-736. PubMed ID: 30102844
[TBL] [Abstract][Full Text] [Related]
6. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys.
Song L; Ma A; Dun H; Hu Y; Fujii Y; Kinugasa F; Oshima S; Higashi Y; Daloze P; Chen H
Am J Transplant; 2017 Mar; 17(3):635-645. PubMed ID: 27598231
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
Wen X; Casey MJ; Santos AH; Hartzema A; Womer KL
Am J Transplant; 2016 Nov; 16(11):3202-3211. PubMed ID: 27137884
[TBL] [Abstract][Full Text] [Related]
8. Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter Trial.
Kaufman DB; Woodle ES; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
Clin J Am Soc Nephrol; 2021 Sep; 16(9):1387-1397. PubMed ID: 34233921
[TBL] [Abstract][Full Text] [Related]
9. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction.
Gupta G; Regmi A; Kumar D; Posner S; Posner MP; Sharma A; Cotterell A; Bhati CS; Kimball P; Massey HD; King AL
Am J Transplant; 2015 Oct; 15(10):2726-31. PubMed ID: 25988397
[TBL] [Abstract][Full Text] [Related]
10. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
[TBL] [Abstract][Full Text] [Related]
11. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
12. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B
Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478
[TBL] [Abstract][Full Text] [Related]
13. Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition.
Alishetti S; Farr M; Jennings D; Serban G; Uriel N; Sayer G; Vasilescu R; Restaino S; Chong AS; Habal MV
Am J Transplant; 2020 Dec; 20(12):3620-3630. PubMed ID: 32506824
[TBL] [Abstract][Full Text] [Related]
14. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
Wojciechowski D; Chandran S; Vincenti F
Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
[TBL] [Abstract][Full Text] [Related]
15. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.
Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2018 Jul; 18(7):1774-1782. PubMed ID: 29573335
[TBL] [Abstract][Full Text] [Related]
16. Clinical aspects of sensitization.
Katznelson S; Bhaduri S; Cecka JM
Clin Transpl; 1997; ():285-96. PubMed ID: 9919412
[TBL] [Abstract][Full Text] [Related]
17. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants.
Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM
Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404
[TBL] [Abstract][Full Text] [Related]
18. Every 2-month belatacept maintenance therapy in kidney transplant recipients greater than 1-year posttransplant: A randomized, noninferiority trial.
Badell IR; Parsons RF; Karadkhele G; Cristea O; Mead S; Thomas S; Robertson JM; Kim GS; Hanfelt JJ; Pastan SO; Larsen CP
Am J Transplant; 2021 Sep; 21(9):3066-3076. PubMed ID: 33583120
[TBL] [Abstract][Full Text] [Related]
19. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295
[TBL] [Abstract][Full Text] [Related]
20. Belatacept Compared With Tacrolimus for Kidney Transplantation: A Propensity Score Matched Cohort Study.
Cohen JB; Eddinger KC; Forde KA; Abt PL; Sawinski D
Transplantation; 2017 Oct; 101(10):2582-2589. PubMed ID: 27941427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
